Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + azacitidine for higher-risk myelodysplastic syndrome
ChiCTR2400094528Phase 4Not yet recruiting
- Sponsor
- Zhenjiang First People's Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor and azacitidine in myelodysplastic syndrome (MDS), sponsored by Zhenjiang First People's Hospital. Primary endpoint: Overall response rate after six cycles of combination therapy. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
selinexorazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2400094528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094528.